Semaglutide (marketed as Ozempic for diabetes and Wegovy for obesity) is a GLP-1 receptor agonist with 94% homology to native human GLP-1 and a half-life of approximately 7 days, enabling once-weekly dosing. Research-grade Semaglutide from QSC is supplied as lyophilized powder for subcutaneous administration.
| Week | Dose | Injection |
|---|---|---|
| 1–4 | 0.25 mg | Once weekly |
| 5–8 | 0.5 mg | Once weekly |
| 9–12 | 1.0 mg | Once weekly |
| 13–16 | 1.7 mg | Once weekly |
| 17+ | 2.4 mg | Once weekly (Wegovy max dose) |
QSC Semaglutide is typically supplied in 2 mg vials. To achieve a 1 mg/mL research solution, add 2 mL bacteriostatic water slowly down the inner glass wall. Each 0.1 mL (10 units on an insulin syringe) = 100 mcg. For a 0.25 mg dose: draw 0.25 mL (25 units). For a 1 mg dose: draw 1.0 mL (100 units).
Semaglutide reaches peak plasma concentration approximately 1–3 days after injection. Steady-state is reached after 4–5 weeks of weekly dosing. It is metabolised proteolytically and excreted renally; no dose adjustment is required for mild-to-moderate renal impairment based on clinical data.
Nausea (44%), vomiting (24%), and diarrhoea (30%) are the most commonly reported adverse events in the STEP trial programme, predominantly during titration. The gradual 4-week per dose escalation schedule in the approved protocol was specifically designed to minimise GI adverse events through receptor desensitisation.
STEP 1 (NCT03548935): 2.4 mg weekly semaglutide produced 14.9% mean body weight reduction vs 2.4% placebo at 68 weeks. STEP 5 demonstrated sustained weight loss maintenance over 104 weeks. These are the primary efficacy reference points for GLP-1 research.
This page is for educational and research purposes only. All products sold by QSC are labelled for research use only and are not intended for human consumption. Nothing on this page constitutes medical advice.